Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Baxter
Daiichi Sankyo
Chinese Patent Office
Julphar
McKesson
AstraZeneca
Covington
Federal Trade Commission

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205993

« Back to Dashboard
NDA 205993 describes POTASSIUM CHLORIDE, which is a drug marketed by Lupin Ltd, Baxter Hlthcare, Abraxis Pharm, Actavis Labs Fl Inc, Hospira, Watson Labs, Kremers Urban Pharms, Genus Lifesciences, Fresenius Kabi Usa, Copley Pharm, Pharma Res Software, Gd Searle Llc, Luitpold, Amneal Pharms, Novel Labs Inc, Sigmapharm Labs Llc, Teva, Schering, Tris Pharma Inc, Nesher Pharms, PII, Pharma Serve Ny, Glenmark Pharms Ltd, Mylan Pharms Inc, Intl Medication, Adare Pharms Inc, Lilly, B Braun, Paddock Llc, Anchen Pharms, Akorn, Miles, and Icu Medical Inc, and is included in seventy-six NDAs. It is available from forty-eight suppliers. Additional details are available on the POTASSIUM CHLORIDE profile page.

The generic ingredient in POTASSIUM CHLORIDE is calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate. There are two hundred and seventy drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate profile page.

Summary for NDA: 205993

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 205993

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
POTASSIUM CHLORIDE
potassium chloride
TABLET, EXTENDED RELEASE;ORAL 205993 ANDA Paddock Laboratories, LLC 0574-0274 0574-0274-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0574-0274-01)
POTASSIUM CHLORIDE
potassium chloride
TABLET, EXTENDED RELEASE;ORAL 205993 ANDA Paddock Laboratories, LLC 0574-0274 0574-0274-05 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (0574-0274-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength8MEQ
Approval Date:Nov 5, 2015TE:AB2RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MEQ
Approval Date:Nov 5, 2015TE:AB2RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
Deloitte
US Army
Covington
AstraZeneca
Healthtrust
Chinese Patent Office
Merck
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot